Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,623 across all filing types
Latest filing 2025-10-30 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-10-30 English
(1) RENEWAL OF CONTINUING CONNECTED TRANSACTIONS&#x3b; AND (2) RENEWAL OF ONE-OFF CONNECTED TRANSACTIONS
Regulatory Filings Classification · 80% confidence The document is an official announcement filed on the Hong Kong Stock Exchange concerning the renewal of continuing connected transactions and one-off connected transactions under Chapter 14A of the Listing Rules. It discloses terms of related-party agreements and annual caps, rather than presenting full financial statements or an investor presentation. This type of related-party transaction disclosure does not fit into any other specific category (e.g., earnings release, proxy materials, annual report, etc.) and is a regulatory announcement. Therefore, it falls under the fallback category “Regulatory Filings” (RNS).
2025-10-30 English
2025 THIRD QUARTERLY REPORT
Interim / Quarterly Report Classification · 100% confidence The document is titled '2025 THIRD QUARTERLY REPORT' for RemeGen Co., Ltd. It contains detailed financial statements, key accounting data, financial indicators, and shareholder information for the third quarter of 2025. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2025
2025-10-30 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 85% confidence The document is a short announcement by RemeGen Co., Ltd. stating the date of a Board meeting to consider and approve its unaudited third quarterly results and publication. It does not contain the actual financial results (so it is not an Interim/Quarterly Report or Earnings Release), nor does it announce changes in board members or management. It simply notifies the timing of report approval and publication. Under the “menu vs meal” rule, such notifications of report timing are classified as Report Publication Announcements (RPA).
2025-10-17 English
DISCLOSEABLE TRANSACTION - PURCHASE OF WEALTH MANAGEMENT PRODUCTS
Capital/Financing Update Classification · 80% confidence The document is an announcement under the Hong Kong Listing Rules regarding a discloseable transaction (Chapter 14) whereby RemeGen Co., Ltd. proposes to purchase bank wealth management products using idle self-owned funds and raised proceeds. It provides detailed terms of the transaction, Board resolutions, listing rules implications and definitions. This is not a financial report, dividend notice, earnings release or share issuance; rather it is a corporate financing/treasury transaction announcement. The best fitting category is “Capital/Financing Update” (CAP).
2025-10-15 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025
Regulatory Filings Classification · 70% confidence The document is a monthly return (Form FF301) filed under Chapter 19B of the HKEX Listing Rules, detailing movements in authorized, issued, and treasury shares. It is a routine regulatory submission rather than an earnings announcement, capital raising notice, or prescribed report like an annual or interim report. No specific share issue or share buyback event is being announced; it simply reports zero movements for the period. Therefore, it falls under the generic regulatory filings category (RNS).
2025-10-08 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.